Once again, lawmakers have introduced legislation to end the tax breaks that drug makers can take for advertising their medicines to consumers, a move that effectively becomes part of a wider package of bills  Democrats are devising rein in the pharmaceutical industry.

The latest attempt comes from Sen. Jeanne Shaheen (D-N.H.), who argues that drug makers are spending too much to market high-priced medicines at a time of growing anger over the cost of prescription drugs. The legislation, called the End Taxpayer Subsidies for Drug Ads Act, would amend the Internal Revenue Code to disallow deductions for such ads.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The average consumer has no idea how the drug companies manniipulate the information on their ads. For doctors to allow themselves to be manipulated by drug representatives is disgusting. Are their any honest people left in this world?

  • Stop the lies, and the drug commercials. Prescribed drugs kill 60K people a year. The cures are blocked. People suffer and die, and all they do Is manage symptoms without curing anyone. Its all about money. Very corrupt.

  • Hey Ed,
    Maybe the lawmakers should end the vig payments the manufacturers have to pay the PBM’s to get their drugs on formulary ! Then increase drug prices to keep their profit margin the same.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy